Impact of the Medicare Modernization Act of 2003 on utilization and spending for medicare part B-covered biologics in rheumatoid arthritis.
OBJECTIVE
To examine changes in utilization and expenditures for infliximab in rheumatoid arthritis (RA) patients associated with the 2 changes implemented by the Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003, specifically 1) reductions in physician reimbursement for Part B drugs between 2003 and 2005 and 2) availability of alternative RA biologics in 2006.


METHODS
Using 2002-2006 5% Medicare files, nationally representative estimates of infliximab use and expenditures were estimated in annual cross-sectional samples of RA beneficiaries. Infliximab initiation and continuation rates were estimated in 2-year longitudinal cohorts (2005-2006 versus 2002-2003, 2003-2004, and 2004-2005).


RESULTS
Total payments (in 2006 dollars) for infliximab increased from $357 million in 2002 to $492 million in 2006. The largest annual increase in infliximab payments occurred in the pre-MMA period from 2002 to 2003, wherein payments per RA patient increased by 31%. From 2003 to 2004, despite the reduction in payments brought by the MMA, there was a 4% increase in total expenditures for infliximab per RA patient driven by an increase in utilization factors. Total payments for infliximab per RA patient actually decreased from 2004 to 2005, when reimbursement was further reduced. Continuation and initiation rates for infliximab use remained unchanged in 2006, as compared with previous years.


CONCLUSIONS
Infliximab expenditures increased from 2002 to 2006, yet the passage of the MMA was associated with a remarkable slowdown in the rate of increase in expenditures. There was no evidence of significant substitution of infliximab with other biologics made available in 2006.
Doshi
Jalpa A
JA
University of Pennsylvania School of Medicine and Leonard Davis Institute of Health Economics, Philadelphia, PA 19104-6021, USA. jdoshi@mail.med.upenn.edu
Li
Pengxiang
P
Puig
Andrea
A
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000191:economics*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001685:Biological Factors / Q000191:economics*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D016345:Medicare Part B / Q000191:economics* / Q000639:trends; D054524:Medicare Part D / Q000191:economics*; D008875:Middle Aged; D012052:Reimbursement, Incentive / Q000191:economics* / Q000639:trends; D014481:United States
D000911:Antibodies, Monoclonal; D001685:Biological Factors; D000069285:Infliximab
J Health Econ. 1991;10(4):385-410
10117011
Adv Health Econ Health Serv Res. 1984;5:129-60
10300352
J Health Polit Policy Law. 1989 Fall;14(3):587-600
2794423
Arthritis Rheum. 2008 Apr;58(4):939-46
18383356
Ann Rheum Dis. 2004 Nov;63(11):1372-8
15020312
J Health Polit Policy Law. 1989 Fall;14(3):601-20; discussion 621-5
2507625
Ann Intern Med. 2008 Jan 15;148(2):124-34
18025440
J Health Polit Policy Law. 1985 Winter;9(4):595-609
3919082
J Health Econ. 1998 Dec;17(6):675-99
10339248
Am J Manag Care. 2005 Mar;11(3):173-80
15786856
Health Serv Res. 1992 Apr;27(1):65-79
1563954
Arch Intern Med. 2006 Jan 9;166(1):57-63
16401811
Med Care. 1983 Aug;21(8):803-15
6350746
Arthritis Rheum. 2004 Dec 15;51(6):952-7
15593102